Cannabis Law Report

JULY 8, 2021

(NYSE American: YCBD, YCBDpA), one of the leading, and most highly trusted and recognized CBD companies, announced today that its recently formed division, cbdMD Therapeutics, has initiated talks with one of the leading US cannabinoid research institutes, to identify novel cannabinoids for therapeutic use. About cbdMD, Inc. cbdMD, Inc.

Research and Development 85

Research and Development Pets Cannabinoids eCommerce 85

NORML

APRIL 4, 2019

Our outdated laws have ruined lives, devastated communities, and wasted resources for critical medical treatment and research. Sixty-eight percent of registered voters “support the legalization of marijuana,” according to 2018 national polling data compiled by the Center for American Progress. ” Said Rep.

Policy 197

Policy Business Research and Development Marijuana 197

Cannabis Law Report

MARCH 21, 2020

Public Safety (PS) is supporting efforts to enforce the legalization and regulation of cannabis through activities to deter criminal activity and to help ensure that organized crime does not penetrate the legalized system. PS is working with the PTs and other key stakeholders (e.g.,

Safety 88

Safety Research and Development Data Cannabis 88

Veriheal

APRIL 11, 2022

federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.

Pharmaceutical 105

Pharmaceutical Research and Development DEA Clinical Trials 105

Cannabis Law Report

JULY 28, 2021

The study was conducted by a respected contract research organization with deep expertise in preclinical oncology model development and drug testing and data corresponding to all studied cancer cell lines have now been reported to the Company. . – July 28, 2021) – PharmaDrug Inc.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

NOVEMBER 2, 2021

Earlier this month, the FDA released a seven-page plan to accelerate its research into the safety of cannabis-derived products. Piloting market surveillance tools to monitor unapproved cannabis-derived products and “identify potential safety issues before the issues become mainstream.”

Safety 52

Safety Data Supply Chain Research and Development 52

Medicinal Genomics

JULY 14, 2022

The truth is that total count tests are not a good indicator of cannabis and hemp product safety for the following reasons: Pathogenic microbes may still be present Testing methods often do not agree Growers are discouraged from using beneficial microbes Growers are encouraged to use remediation. fumigatus, A.

Safety 92

Safety Research and Development Concentrates Food 92

Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. MYMD-1 is being developed to treat autoimmune and age-related diseases, and to slow aging thereby increasing life-span. Acumen Research and Consulting confirmed TNF-? President, Director and Chief Medical Officer of MyMD.

Pharmaceutical 81

Pharmaceutical Data Clinical Trials Research and Development 81

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Veriheal

AUGUST 7, 2022

New data published in the Journal of Cannabis Research claims that almost one in two authorized medical cannabis patients in Canada managed to either completely stop or reduce their intake of controlled substances, such as alcohol and opioids , by using cannabis. As of 2020, the market was worth CAD $2.6 billion (USD $2 billion).

Consumption 111

Consumption Patients Research and Development Data 111

The Cannigma

FEBRUARY 2, 2021

In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. Still, research is ongoing. Parkinson’s disease and cannabis. The effectiveness of cannabis for Parkinson’s disease.

Patients 111

Patients Clinical Trials Research and Development Treatment 111

Cannabis Law Report

SEPTEMBER 9, 2021

WHAT: During the session, “ Cannabis Moves Toward the Mainstream ,” Nielsen will share IRI and BDSA’s predictions for mainstream market opportunities, cannabis ingredients, product development, labeling and safety. . . WHEN: Cross Channel Measurement in a Time of Data Collection Challenges. . 20, 2021, from 2:40 – 2:55 p.m.

Events 78

Events Wellness and Beauty Data Media 78

Cannabis Law Report

AUGUST 22, 2021

But for now, the developers are focused on creating a training that emphasizes compassionate response, de-escalation, and the safety and well-being of individuals having a challenging time with a psychedelic experience. Interesting piece from Lucid news. Read the full report at .

Research and Development 105

Research and Development Decriminalization Education Safety 105

Cannabis Law Report

MAY 18, 2022

Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. Validcare contracted with 17 CBD companies and acted as the Contract Research Organization, which included gaining feedback from FDA on the protocol, conducting the study and publishing its results.

Safety 52

Safety Hemp Research and Development Data 52

Veriheal

JANUARY 16, 2024

Let’s take a closer look at this new research around CBD for Cerebral Palsy and examine the extent of this trend and its implications for the future of CP management. It occurs due to abnormalities or damage to the developing brain before, during, or after birth. What is Cerebral Palsy?

Patients 116

Patients CBD Treatment Research and Development 116

Canna Law Blog

JULY 25, 2019

For the past six months, the federal agency has been bombarded with messages, urging the FDA to promptly develop a regulatory pathway for the lawful use of hemp-derived CBD (“Hemp-CBD”) in foods and dietary supplements. The Food and Drug Administration (“FDA”) seems to be listening.

CBD 99

CBD Research and Development Hemp Food 99

Cannabis Law Report

MAY 18, 2022

NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE , AMPLIFIES CALLS FOR FDA REGULATION. Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. The study abstract is available here. The methods for both phases were the same.

Safety 52

Safety Hemp Research and Development Data 52

LifeCannMD

MAY 27, 2025

Researchers followed chronic pain patients and found something fascinating: the group using just 2.5 A leading researcher in cannabis medicine documented something fascinating called the “biphasic effect.” With cannabis, we’re talking about tiny amounts maybe 1 to 5 milligrams of THC, sometimes even less.

Microdosing 52

Microdosing Research and Development Sleep Chronic Pain 52

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients. About RYAH Group, Inc.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Veriheal

NOVEMBER 21, 2023

Scientific research supports the potential of cannabinoids in regulating blood sugar levels, weight management, and addressing diabetic neuropathy. Maya worked with a group of her peers to develop the buddie Bluetooth cannabis bowl.

Research and Development 110

Research and Development Consumption Education Data 110

Veriheal

MAY 16, 2022

Researchers working at the University of Arizona College of Medicine in Tucson have refined a method of ketamine use in the treatment of Parkinson’s disease (PD). Once known solely as a party drug, ketamine is starting to earn a new reputation thanks to research efforts into its potentially medicinal qualities.

Research and Development 19

Research and Development Treatment Clinical Trials Patients 19

Cannabis Law Report

NOVEMBER 29, 2021

Medical marijuana has received more attention from legislators, scientists, researchers, clinicians, and the general public than any other topic. . Advocates claim that legalizing decreases crime rates, lowers criminal justice expenses, improves public health, generates tax revenue, enhances traffic safety, and promotes the economy. .

Legalization 52

Legalization Research and Development Decriminalization Marijuana 52

Cannabis Law Report

AUGUST 27, 2021

The Board will advise Delic and its subsidiaries, including Ketamine Infusion Centers, Delic Labs and others, as they develop safety protocols and best practices pertaining to legal psychedelic wellness treatments today and those legalized in the future.

Research and Development 98

Research and Development Treatment Media Medicine 98

Cannabis Law Report

AUGUST 10, 2021

–(BUSINESS WIRE)– PSI Labs , an Ann Arbor, Michigan-based ISO 17025 accredited Safety Compliance Facility that provides essential cannabis testing services, today announced its expansion into Southern California with the acquisition of pH Solutions, LLC. Monrovia-Based Lab Acquisition Strengthens Cannabis Testing In California.

Research and Development 81

Research and Development Compliance Compliance Safety 81

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.

DEA 51

DEA Clinical Trials THC Research and Development 51

Veriheal

MARCH 14, 2022

Cannabis and driving could be a recipe for disaster, say researchers from the Center for Medicinal Cannabis Research in the University of California San Diego. . hours post smoking,” wrote the researchers responsible for carrying out this two-year randomized trial study. . Although performance was improving at 3.5

Research and Development 98

Research and Development Consumption THC Concentrates 98

Cannabis Law Report

JULY 28, 2021

Producing deep-dive policy and operational research and analysis on priority initiatives. Collaborating with County departments, community leaders and other agencies to obtain data, provide analysis and convey results that support the Supervisor’s policy agenda. Present materials in a digestible way for different audiences.

Policy 81

Policy Legislation Research and Development Data 81

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 40

Epilepsy Pharmaceutical Data Clinical Trials 40

Puff Puff Post

MARCH 10, 2020

“We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs. For more information, visit www.inmedpharma.com.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Adverse mental events were reported as well, however, more research should be performed to assess well this outcome.

Safety 52

Safety Cannabinoids Data Events 52

The Cannigma

JUNE 29, 2021

Though the distinction between these terms may seem trivial at first glance, it is in fact crucial for cannabis research, and therefore also for consumers and regulators as well. Researchers conducting survey based studies today often only have access to the THC concentration of the cannabis that their participants are using.

Terpenes 138

Terpenes Research and Development Cannabinoids Concentrates 138

Cannabis Law Report

SEPTEMBER 1, 2021

This number also underscores the entire agency’s tireless efforts, particularly those of our hardworking staff, to thoughtfully regulate a safe, accessible, and effective adult-use marketplace that keeps critical tenets of our mission – public health, public safety, and equity, among others – front of mind.”.

Marijuana 100

Marijuana Seed-To-Sale Safety Data 100

Cannabis Law Report

JUNE 16, 2021

Genetic Screening Platform Technology and Data to Strengthen Entheon’s Psychedelic-Assisted Protocols. Lobo brings a highly experienced and specialized team of technology experts in the fields of genetics, diagnostics, data and analytics, as well as a fully operational 5,000 sq. Vancouver, British Columbia–(Newsfile Corp.

Research and Development 105

Research and Development Data Conditions Events 105

Cannabis Law Report

JANUARY 31, 2022

TSX-V:NUMI, OTC:LKYSF) said that its research facility– Numinus Bioscience– has been included on Health Canada’s list of federally licensed psilocybin producers. This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. Numinus Wellness Inc.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

AUGUST 11, 2021

HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations. With a strong focus on research and development, HempFusion has an additional 30 products under development.

Research and Development 81

Research and Development Tincture Food Hemp 81

Cannabis Law Report

AUGUST 10, 2021

The UK is a significant country for us for many reasons, and we are proud to be able to offer a medicine, that has been developed and is manufactured here, to even more patients across the UK. The safety profile observed was consistent with findings from previous studies, with no new safety risks identified.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98